Vertex Pharmaceuticals Incorporated
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000C1S2X2
VRTX
Vertex Pharmaceuticals Incorporated
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Vertex Pharmaceuticals Incorporated
ISIN
US92532F1003
TICKER
VRTX
MIC
XNAS
REUTERS
VRTX.OQ
BLOOMBERG
VRTX US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mo., 04.11.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion.
“The third quarter marked another period of strong progress, with continued revenue growth and outstanding execution a...
Vertex Pharmaceuticals
Di., 29.10.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:00 a.m. ET.
Stuart A...
Vertex Pharmaceuticals
Fr., 25.10.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates demonstrate the transformative potential of Vertex’s investigational therapies in multiple serious kidn...
Vertex Pharmaceuticals
Fr., 18.10.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place ...
Vertex Pharmaceuticals
Do., 10.10.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Ver...
Vertex Pharmaceuticals
Do., 26.09.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor (“vanza triple”) — the potential next-in-class triple combination medicine — will take place at the North American Cystic Fibrosis Conference (NACFC)....
Vertex Pharmaceuticals
Do., 22.08.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
Dr. Reshma Kewalramani, Chief Executive Officer and President, and Charles Wagner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global He...
Vertex Pharmaceuticals
Informationen zu Product Placements
